Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
Ozempic and Wegovy: Scientists Uncover New Risks of Popular Weight-Loss “Miracle Drugs”
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,
The mechanism behind behavioral side effects of popular weight loss drugs
Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been linked with behavioral side effects.
Major study of weight-loss jabs shows slew of benefits but also risks
The risk of heart attack and stroke declines, but gastrointestinal problems and joint inflammation increase: New research has shed more light on the pros and cons of weight-loss jabs.
Researchers reveal benefits, risks linked to popular weight-loss drugs
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,
Ozempic’s health benefits keep growing, but are the risks worth it?
A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.
Websites selling compounded GLP-1 RAs often misinform consumers, research reveals
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...
HealthDay on MSN1d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the ...
What’s wrong with Apple now?
There’s a little problem, though: most of the decline in the seven comes down to one company. Apple is down 14 per cent since ...
Medscape21h
GLP-1 Benefits, Risks Detailed in ‘Atlas’ Mapping Outcomes
The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...
Insurance coverage and type of employment shape inequities in access to semaglutide
Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...
Too Old to Operate1d
GLP1RA Use Increases Solid RGCs and Aborted Procedures in Endoscopy
The following is a summary of “Endoscopy and Anesthesia Outcomes Associated with Glucagon-Like Peptide-1 Receptor Agonist Use ...
phillyvoice.com1d
Ozempic and Wegovy are helping many Americans lose weight, but they also may have other beneficial uses
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...